Immunic (IMUX) News Today $0.73 +0.02 (+2.24%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.73 +0.00 (+0.27%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Immunic CEO discusses Phase 2 multiple sclerosis study success - ICYMIJune 28, 2025 | proactiveinvestors.comD. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)June 25, 2025 | marketbeat.comImmunic reveals long-term data supporting potential of MS drug vidofludimus calciumJune 24, 2025 | proactiveinvestors.comImmunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple SclerosisJune 24, 2025 | prnewswire.comImmunic showcases MS drug data at BIO International Convention in Boston - ICYMIJune 21, 2025 | proactiveinvestors.comImmunic, Inc. (NASDAQ:IMUX) Chairman Duane Nash Purchases 20,000 SharesJune 17, 2025 | insidertrades.comInsider Buying: Immunic, Inc. (NASDAQ:IMUX) Chairman Purchases 20,000 Shares of StockJune 16, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Short Interest UpdateJune 15, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by BrokeragesJune 11, 2025 | marketbeat.comImmunic Post-Readout: Reiterating Strong Buy As Big Drop Appears UnwarrantedJune 9, 2025 | seekingalpha.comMillennium Management LLC Has $580,000 Stake in Immunic, Inc. (NASDAQ:IMUX)June 9, 2025 | marketbeat.comImmunic completes Phase 3 multiple sclerosis trial enrollment - ICYMIJune 7, 2025 | proactiveinvestors.comInsider Buying: Immunic, Inc. (NASDAQ:IMUX) CEO Purchases 15,000 Shares of StockJune 6, 2025 | marketbeat.comImmunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trialsJune 5, 2025 | proactiveinvestors.comImmunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MSJune 5, 2025 | prnewswire.comQ2 Earnings Forecast for Immunic Issued By Leerink PartnrsJune 5, 2025 | marketbeat.comImmunic raises $65M in public offering to fund clinical trialsJune 3, 2025 | proactiveinvestors.comImmunic raises $65M in public offering to fund clinical trialsJune 3, 2025 | proactiveinvestors.comImmunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public OfferingJune 3, 2025 | prnewswire.comImmunic to Participate in Investor, Scientific and Industry Conferences in JuneJune 2, 2025 | prnewswire.comD. Boral Capital Cuts Immunic (NASDAQ:IMUX) Price Target to $10.00May 30, 2025 | marketbeat.comImmunic announces public offering of warrants to fund trialsMay 30, 2025 | investing.comImmunic shares fall 12% after pricing of $65 million underwritten public offering to fund trialsMay 29, 2025 | msn.comImmunic unveils pricing of $65M underwritten public offeringMay 29, 2025 | proactiveinvestors.comImmunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public OfferingMay 29, 2025 | prnewswire.comImmunic, Inc. Announces Proposed Public OfferingMay 28, 2025 | prnewswire.comImmunic (NASDAQ:IMUX) Receives Buy Rating from B. RileyMay 25, 2025 | marketbeat.comImmunic Analyst Ratings and Price Targets | NASDAQ:IMUX | BenzingaMay 24, 2025 | benzinga.comJanus Henderson Group PLC Cuts Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)May 23, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by AnalystsMay 19, 2025 | marketbeat.comImmunic (IMUX) Expected to Announce Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comWilliam Blair Analysts Boost Earnings Estimates for ImmunicMay 6, 2025 | marketbeat.comLeerink Partnrs Has Bullish Estimate for Immunic Q2 EarningsMay 6, 2025 | marketbeat.comResearch Analysts Issue Forecasts for Immunic Q1 EarningsMay 4, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Receives "Buy" Rating from HC WainwrightMay 3, 2025 | marketbeat.comImmunic Reports Positive Data From Phase 2 CALLIPER Study Of Vidofludimus CalciumMay 2, 2025 | nasdaq.comD. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX)May 2, 2025 | marketbeat.comImmunic to Participate in Scientific and Industry Conferences in MayMay 2, 2025 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Shares Sold by Adage Capital Partners GP L.L.C.May 2, 2025 | marketbeat.comImmunic drops after mid-stage trial data for multiple sclerosis drugMay 1, 2025 | msn.comImmunic reports reduced disability worsening in progressive multiple sclerosis trialApril 30, 2025 | proactiveinvestors.comImmunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER TrialApril 30, 2025 | prnewswire.comImmunic: A Strong Buy With Imminent Data Readout That Should Send Shares HigherApril 28, 2025 | seekingalpha.comOne Immunic Insider Raised Their Stake In The Previous YearApril 25, 2025 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from BrokeragesApril 24, 2025 | marketbeat.comEquities Analysts Set Expectations for Immunic Q1 EarningsApril 20, 2025 | marketbeat.comFY2025 Earnings Estimate for Immunic Issued By HC WainwrightApril 19, 2025 | marketbeat.comImmunic, Inc. Common Stock (IMUX)April 18, 2025 | nasdaq.comB. Riley Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX)April 18, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Immunic Q1 Earnings?April 18, 2025 | marketbeat.com Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUX Media Mentions By Week IMUX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼1.000.54▲Average Medical News Sentiment IMUX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼14▲IMUX Articles Average Week Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aerovate Therapeutics News 2seventy bio News Rocket Pharmaceuticals News ADC Therapeutics News Corvus Pharmaceuticals News Alpha Teknova News Tonix Pharmaceuticals News Foghorn Therapeutics News COMPASS Pathways News Annexon News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
